PTPI - Petros Pharma Total Debt to Capital

Petros Pharmaceuticals (PTPI) generates revenue from the sale of men's health products, seeking to expand its presence in the OTC segment through digital marketing. However, a narrow product portfolio and pressure from generics hinder growth, while R&D costs remain high. This chart shows the market price of the separate_debt_total_eq metric is 0.00, highlighting the company's vulnerability to expansion by major telemedicine platforms.

Investors are assessing the stability of Petros Pharmaceuticals (PTPI) through the balance of debt and equity, where this ratio measures the proportion of credit load within the capital structure to determine financial leverage. By analyzing the ratio of total liabilities to shareholders' equity, one can understand how effectively the digitalization of pharmacology is being funded by debt, which is critical for assessing the risk of cash flow gaps during the scaling of IT platforms.